Medical Hypothesis, Discovery and Innovation Ophthalmology Journal
Volume:5 Issue: 1, Spring 2016

To investigate the safety profile and benefits of a short-term simultaneous treat-ment combining two drugs: an intravitreal implant of dexamethasone with an intravitreal in-jection of bevacizumab in patients with macular edema, this study was performed.
This was a retrospective, non-randomized, open-label case series study. Patients were treat-ed between April 2014 and July 2015 and were diagnosed with recurrent macular edema secondary to diabetic retinopathy and retinal vein occlusion. They underwent simultaneous treatment with an intravitreal injection of bevacizumab (1.25 mg) and an intravitreal implant of dexamethasone (0.7 mg). Patients were evaluated at baseline and at each subsequent visit with a complete ophthalmological examination and spectral-domain optical coherence to-mography (OCT) scans. They were examined 24 hours after the treatment, and then followed up after 30 days and 60 days.
Twenty patients (representing 20 eyes) were included in the study. At the time of injection (i.e., baseline), the best-corrected visual acuity (BCVA) was 0.758 0.42 logarithm of the minimum angle of resolution (logMAR). It improved statistically significantly to 0.51 0.33 logMAR at 1 month and to 0.5 0.34 logMAR at 2 months (p ? 0.03). The median baseline central macular thickness (CMT) was 542 m (interquartile range, 466751 m). The median CMT decreased statistically significantly to 321 m (interquartile range, 288381 m) at 1 month, 310 m (interquartile range, 286354 m) at 2 months (p ? 0.0002). The mean intraocular pressure (IOP) increased from 14.9 2.29 mmHg (at baseline) to 16.5 2.99 mmHg (p = 0.04) after 2 months. Two (10%) eyes had cataract progression. There were no other ocular or systemic complications for the duration of this study.
In conclusions, simultaneous therapy combining a dexamethasone implant plus bevaci-zumab for macular edema may be an attractive treatment regimen with an acceptable safety profile.

We report a 32-year-old man with Behts disease who had simultaneous bilateral anterior uveitis, unilateral nodular scleritis and occlusive vasculitis with retinal hemorrhages at the same time. Though scleritis is not considered within the classical features of Behts disease Behts disease should be contemplated in the scleritis etiology.

To review the available data regarding the current management of non-complex rhegmatogenous retinal detachment and to propose a new decision-making algorithm aimed to improve the single surgery success rate for mid-severity rhegmatogenous retinal detachment, this study performed.
An online review of Pubmed database was performed, searching for all available manuscripts regarding anatomical and functional outcomes after the surgical management of retinal detachment either by scleral buckle or primary pars plana vitrectomy. The search was limited to articles published since 1995 to date. All returned articles were carefully screened and their references were manually reviewed for additional relevant data. Our search specifically focused on preoperative clinical data which were associated with the surgical outcomes. After categorizing the available data according of their level of evidence; being randomized clinical trial the highest possible level of evidence, followed by retrospective studies and finally retrospective case series as the lowest level of evidence; we proceeded to design a logical decision-making algorithm, enhanced with our experience as retina surgeons.
A total of 7 randomized clinical trials, 19 retrospective studies and 9 case series were considered. Additional articles were also included in order to further support the observations.
Rhegmatogenous retinal detachment is a potential blinding disorder. Its surgical management seems to depend more on surgeons preference than solid scientific data or good clinical history and examination. The algorithms proposed herein strive to offer a more rational approach while improving both anatomical and functional outcomes after the first surgery.

In modern pharmacological medicine, saffron is used for various purposes due to its antioxidant effect. This study evaluated retinal function after treatment with saffron supplementation during a follow-up period of 6 months to provide further insight into the efficacy and safety considerations of this treatment.
Sixty patients with wet or dry age-related macular degeneration (AMD) were randomly assigned to oral saffron 30 mg/d or placebo supplementation for 6 months. Optical coherence tomography (OCT), electroretinography (ERG), fluorescein angiography (FA), and visual acuity (VA) testing were recorded at baseline, 3 months, and 6 months after treatment. The main outcome measures were OCT, ERG amplitude, and implicit time.
Six months after treatment, no statistically significant decrease in OCT resultswas observed between the groups with dry AMD (p=0.282). However, there was a statistically significant increase in ERG results between thegroups at 3 months (p=0.027). In addition, there was a statistically significant decrease in OCT results between groups with wet AMD atfollow-up (p=0.05). Finally, there was a statistically significant increase in ERG findings between the groups with wet AMD at 3 months (p=0.01), but these changes decreased after 6 months (p=0.213).
In conclusion, daily supplementation with 30 mg of saffron for 6 months may induce a mid-term, significant improvement in retinal function in patients with AMD.